Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques

BACKGROUND: Tecovirimat (ST-246) is being developed as an antiviral therapeutic for smallpox for use in the event of an accidental or intentional release. The last reported case of smallpox was 1978 but the potential for use of variola virus for biowarfare has renewed interest in smallpox antiviral...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Russo, Andrew T, Grosenbach, Douglas W, Brasel, Trevor L, Baker, Robert O, Cawthon, Andrew G, Reynolds, Erin, Bailey, Tara, Kuehl, Philip J, Sugita, Victoria, Agans, Krystle, Hruby, Dennis E
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151088/
https://ncbi.nlm.nih.gov/pubmed/29982575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy326
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars